Salesforce | January 27, 2021
Salesforce, [NYSE: CRM], the worldwide pioneer in CRM, today reported Vaccine Cloud, innovation to help government offices, healthcare associations, organizations, philanthropies and instructive foundations all the more quickly, securely and productively send and deal with their vaccine programs. Today, global, government, state and neighborhood organizations, healthcare suppliers and charities overall are utilizing Salesforce innovation explicitly for vaccine organization, including Northwell Health, Illinois' Lake County, University of Massachusetts Amherst, Gavi, the Vaccine Alliance and then some.
Presently that protected and viable COVID-19 vaccines are accessible, each nation, state and city is quickly setting up inoculation projects to get shots in the arms of billions of individuals. In any case, numerous administration offices and healthcare associations don't have the innovation framework set up to deal with the multifaceted nature, speed and scale important for vaccine organization, for example, stock and coordinations management, getting individuals enrolled and booked for their vaccines, and beneficiary effort and vaccine result checking. Governments are additionally collaborating with private area organizations to help deal with this mass immunization exertion, and these organizations need a similar innovation foundation to help convey protected, productive and viable vaccine organizations and projects.
"The biggest challenge the world faces right now is orchestrating the distribution of billions of vaccine doses. Technology can play a critical role in ensuring it's done efficiently, effectively, and equitably," said Bret Taylor, President and COO of Salesforce. "We're proud to be supporting organizations through their recovery and helping to protect people from the effects of COVID-19."
ABOUT VACCINE CLOUD
Vaccine Cloud is part of Salesforce's COVID-19 response technology solutions, which include vaccine inventory management, appointment scheduling, outcome monitoring, public health outreach and more.
Salesforce, the global CRM leader, empowers companies of every size and industry to digitally transform and create a 360° view of their customers.
FUTURE OF HEALTHCARE
MedX Health Corp. | November 22, 2021
MedX Health Corp. (“MedX” or the “Company”) and Al Zahrawi Medical Supplies LLC ("Al Zahrawi") are pleased to announce a Memorandum of Understanding between the companies on a two-phase commercialization pilot and distribution agreement for MedX’s leading-edge DermSecure® Screening Platform at select United Arab Emirates (“UAE”) oncology and dermatology clinics beginning this month.
The three-month pilot will involve an estimated 1,000 patients at four dermatology and oncology clinics in Abu Dhabi and Dubai. Upon the successful completion of the two phases, the MedX DermSecure® Screening Platform will become more widely available at clinics and health care facilities across the UAE. As the largest distributor of medical devices in the Gulf Cooperation Council (GCC) region, the partnership with Al Zahrawi positions MedX for continued growth in other Middle Eastern markets including Saudi Arabia, Qatar, Oman, and Bahrain. This initiative is the latest in a series of commercialization pilots recently launched in Europe and the Middle East as part of MedX’s global commercialization strategy, building on pilots underway in the Netherlands, Italy and Turkey. Additional commercialization pilots are anticipated in the coming months.
“At Zahrawi, we are passionate about providing the highest quality products and services to healthcare facilities and laboratories across the GCC,” said David Fawzy Yassa, Business Development Director at Al Zahrawi. “MedX’s teledermatology platform meets these high standards, with a proven ability to improve outcomes for dermatology patients. We’re eager to work with MedX to bring the platform to more patients across the UAE market and other GCC nations.”
Teledermatology is a subspeciality of dermatology that offers safe and effective virtual care – patient screening and assessment – eliminating the need for in-person appointments with a dermatologist. Unlike other teledermatology screening tools available, MedX’s DermSecure® Screening Platform features high-resolution image capture technology for moles, lesions and other skin conditions, providing a complete, virtual dermatological assessment by a certified dermatologist within just 72 hours.
MedX’s leading telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy® is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface.
“This pilot is a significant step forward in growing MedX’s global presence, particularly among countries in the GCC region. During this time of rapid growth for our company, we look forward to working with trusted partners like Al Zahrawi to expand our global footprint and improve more patient outcomes.”
Sylvain Desjeans, MedX CEO
Naman Demaghlatrous, MedX Managing Director of Europe, Middle East and Africa, added, “Our pilot in the UAE is an important foothold in the GCC region – it represents the first of six markets we want to penetrate in the Middle East. Following the successful completion of this UAE pilot, we’ll be seeking other similar opportunities in Saudi Arabia and other GCC nations in the months ahead.”
According to Omnia Health, melanoma skin cancer is of growing concern in the UAE as one of the most common malignancies in men, with an incidence rate of 14.5%.1 The World Health Organization estimates that cancer rates in the Middle East will double by 2030.2 Early and rapid detection of melanoma is key to improving patient outcomes.
About MedX Health Corp
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey.
About Al Zahrawi Medical Supplies LLC
Zahrawi Group is a leading company dedicated to contributing to the UAE, KSA, Qatar, Bahrain and Oman markets by supplying high-quality products and services to hospitals, clinics, laboratories and analytical industries. Zahrawi Group is continuously expanding, progressing and contributing to the prosperity of the people and economy of the region. Zahrawi Group represents an extensive profile of internationally renowned Healthcare and Laboratory manufacturers, such as Medtronic, Agilent Technologies, Dako, Sakura, BD, Sysmex, Cepheid, Hitachi, Sebia and many others. Zahrawi Group continues to show sustainable growth year over year with Dhs 583 Million in revenues in 2020.
Medigate | March 24, 2021
Medigate, healthcare-focused device security, and asset management company, has partnered with Rapid7. Both companies are committed to ensuring real-time health. The joint approach will provide healthcare delivery organizations (HDOs) with never-before-seen vulnerability management insights, allowing them to develop best practices.
Every day, healthcare institutions operate on clinical networks that provide a combination of conventional medical and IoT devices connected from a number of locations, making it extremely difficult to gain complete visibility into the environment and make informed choices on how to manage these critical assets. Medigate's IoT security platform will be integrated with Rapid7 InsightVM and Nexpose vulnerability management systems as part of this collaboration, allowing HDOs, clinics, and other HIPAA-covered entities to control connected assets in a secure manner.
“Healthcare organizations are becoming increasingly vulnerable to cyber-attacks given their high-value data and often disparate IT systems,” said David Beaver, director of strategic alliances and partnerships at Rapid7. “As the IT and IoMT landscape continues to evolve, there must be a focus on investment in cyber defense to protect patients and their data. We are thrilled to partner with Medigate to bring safety and security together through visibility, assessment, and governance.”
Todd Felker, director of information security at Torrance Memorial Medical Center commented, “The integration between Rapid7 (vulnerability management) and Medigate is crucial and helps on both fronts. It saves you money on the number of IPs to be scanned by Rapid7 by having Medigate provide the IoT scanning exclusions, and it provides accurate vulnerability data on the Medigate-side with the servers and computers that integrate with your medical devices. It’s all about having the tools that you invest in working together to provide better data and run more efficiently.”
The advantages of Medigate and Rapid7's interconnected solution come from a bi-directional data integration scheme that delivers constantly refreshed, completely coordinated intelligence to each system, powering healthcare security and asset management ecosystems. Eventually, the collaboration allows core areas of interoperability, which improves efficiencies, lowers costs, and improves patient safety.
“As healthcare organizations adopt new digital innovations and new advances – such as telehealth – they must also embrace the security protocols and framework to protect this technology and guard against clinical risks,” said Jonathan Langer, CEO of Medigate. “Our partnership with Rapid7 is critical for our healthcare customers who are increasingly under attack. It’s essential they have the tools to protect themselves and take action as warranted. By combining the power of Rapid7’s robust cybersecurity with Medigate’s clinical knowledge and insights, we’re not only allowing for better device management but taking proactive steps to achieve true security at all levels of the hospital.”
Medigate is the first and only dedicated medical device security and asset management platform in the industry, allowing providers to deliver safe, connected care. Medigate combines the reality of today's cybersecurity threats with knowledge and understanding of medical workflow and system identity and protocols. Hospital networks may use Medigate to efficiently manage all medical devices on their network, allowing for the deployment of current and new devices to patients while maintaining patient privacy and security.
About Rapid 7
Rapid7 is advancing security with visibility, analytics, and automation delivered through its Insight cloud. Their solutions simplify the complex, allowing security teams to work more effectively with IT and development to reduce vulnerabilities, monitor for malicious behavior, investigate and shut down attacks, and automate routine tasks. Over 9,700 customers rely on Rapid7 technology, services, and research to improve security outcomes and securely advance their organization.